Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Oncology Biosimilars Portfolio by Year
Oncology Biosimilars Portfolio (Ruxience, Zirabev, Trazimera, Nivestym, Nyvepria) — U.S. reported YoY (%) (%)
Pfizer Oncology Biosimilars Portfolio: 46.0% in FY2025, up 81.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Oncology biosimilars (g) | 1,301 | 1,037 | 25% | 26% | 914 | 628 | 46% | 387 | 409 | (5%) | (5%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Oncology Biosimilars Portfolio (Ruxience, Zirabev, Trazimera, Nivestym, Nyvepria) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.0% | +81.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -35.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Pfizer Oncology Biosimilars Portfolio (%), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/onc-biosim-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.